DSGN: Design Pharma Price to Sales
High profit margins are supported by the precise delivery of biomaterials and temperature control. The current price-to-sales ratio clearly demonstrates market expectations, where serves as the base parameter value. Investors trust the small molecule developments for combating hereditary pathologies, while a staff of leading biologists is retained through a system of premium options for Design Therapeutics (DSGN).
Analytical breakdowns for Design Pharma (DSGN)
- share price and consensus valuation forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Design Therapeutics|DSGN - Long-Term Debt to Capital|Current Liabilities to Capital Design Corp|DSGN - Company Total Debt|Debts to Book Capitalization Design Pharma|DSGN - Company Long-Term Liabilities|Amount of Current Liabilities Design Therapeutics|Interim Coverage Ratio designtx.com
- earnings and valuation multiples information:
DSGN - Net Profit|Future Profit Design Therapeutics|DSGN - Price to Earnings Ratio|Market Cap to Projected Earnings Design Therapeutics Inc|DSGN - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Design Pharma|DSGN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Design Therapeutics|DSGN - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year designtx.com|DSGN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Design Therapeutics
- issuer revenue and sales details:
Summary company analytics:DSGN designtx.com
The P/S ratio of reflects the market value of Design Therapeutics relative to its revenue, measuring the extent of business overvaluation or undervaluation through the ratio of market capitalization to sales. By analyzing historical P/S levels, an investor can identify asset overheating, which is critical for DSGN as the current valuation is based on future gene therapy validation and the success of clinical trials.
Who Design Therapeutics competes with
TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|P/S Multiple QGEN (Qiagen)|Ionis Pharmaceuticals, Inc. (IONS) - Price to Sales|RGEN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio RNA (Avidity Corp)|CRSP: P/S Multiple|genedx.com (WGS) - P/S Multiple|Price-to-Revenue Ratio Ultragenyx|Beam Therapeutics Inc - Price-to-Sales Ratio|P/S Multiple SRPT|TWST - Price to Sales|10x Genomics, Inc. - Market Cap to Revenue|P/S Multiple intelliatx.com NTLA|STOK: Market Cap to Revenue|BioLife Solutions Inc - Market Cap to Sales Volume|WVE: P/S Multiple|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics Inc) - P/S Multiple|Market Cap to Revenue primemedicine.com (PRME)|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Price-to-Revenue Coefficient uniQure NV|P/S Multiple MGTX (MeiraGTx PLC)|RGNX: Market Cap to Revenue Ratio|SLDB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ocugen.com OCGN|PACB: P/S Multiple|Price-to-Revenue Multiple Benitec Biopharma Inc BNTC|Price-to-Revenue Ratio Rocket Pharmaceuticals Inc|Market Cap to Revenue Ratio FDMT (4D Molecular Corp)|P/S Multiple LXEO|korrobio.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Editas Medicine EDIT|SLN: Market Cap to Revenue Ratio|ProQR Therapeutics NV - P/S Multiple|CDXS - P/S Multiple|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|MGX (Metagenomi) - P/S Multiple|Price to Sales precisionbiosciences.com DTIL|Price-to-Revenue Ratio Generation Bio Co. (GBIO)|Price-to-Revenue Coefficient Boundless Bio Inc|P/S Multiple XCUR (Exicure)|Price-to-Revenue Coefficient Imunon Inc (IMNN)|RXi Pharmaceuticals - P/S Multiple|Price-to-Revenue Multiple Mustang Bio, Inc. (MBIO)|transcodetherapeutics.com (RNAZ) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio BNGO|Market Cap to Revenue APDN|BLUE: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|Market Cap to Sales Volume OMGA|P/S Multiple OMIC (Singular Genomics Systems Inc)|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|Price to Sales telesisbio.com|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology Inc. - Market Capitalization-to-Revenue Ratio
